Further evidence that early loss of specific cell cycle checkpoint kinases essentially serves as a decision point for evolution of cancers with specific prognostic and progressive tendencies may argue for an improved system of cancer classification based on the mode of cell cycle checkpoint inactivation to guide selection of therapeutics. This evidence concerns the gene CHEK1 and cancer.